Hemophilia C

If you have hemophilia C, you have a deficiency of FXI. Hemophilia C is usually hereditary and affects both genders equally. In rare cases, it can be acquired due to another disease state, such as lupus. After vWD, hemophilia A, and hemophilia B, it is the fourth most common bleeding disorder and is thought to affect 1 in 100,000 of the adult population. Unlike the other bleeding disorders, hemophilia C occurs more predominantly in one demographic: Jewish people of Ashkenazi (or Eastern European) descent, where it is estimated to affect 8% of the population.

Joint and muscle bleeds are not common with hemophilia C. Hemophilia C symptoms can vary and might not be related to your FXI level, and bleeds may occur after surgery, dental procedures, or trauma, but bleeding tendencies are unpredictable and inconsistent.

Hemophilia C is also called plasma thromboplastin antecedent deficiency, PTA deficiency, or Rosenthal syndrome. Hemophilia C can affect any demographic, but a higher number of individuals of Ashkenazi Jewish descent and the Basque population of Southern France are affected.

Hemophilia C (FXI deficiency) has an autosomal recessive inheritance pattern, which means that both parents need to be carriers of the mutated gene to pass it on to their children.

Hemophilia C is caused by a deficiency of coagulation FXI and has autosomal recessive inheritance. It is not completely recessive because if either parent had the defective gene, their offspring might still have a FXI deficiency and excessive bleeding.

Acquired hemophilia C can develop due to an immunologic response or an additional disease state, like systemic lupus erythematosus or Noonan syndrome, which causes inhibitors to the FXI protein.

Symptoms and Diagnosis

If you have hemophilia C, you likely won’t have spontaneous bleeds, and bleeding tendency can be mild. However, you may have hemorrhaging or prolonged bleeding after a major surgery or a serious enough injury. In addition, you may have some of the following symptoms:

• Oral bleeding, especially after dental surgery or tooth extraction
• Nosebleeds
• Easy bruising
• Blood in the urine
• Post-partum hemorrhage
• Excessive bleeding upon removal of tonsils
• Bleeding after circumcision
• Hematomas after surgery
• Menorrhagia (heavy or prolonged menstrual bleeding: longer than 5 days, more than 90 ml of bleeding, and/or clots larger than a grape)
• Bleeding in the gut (less common)
• Blood in the urine (less common)

To diagnose hemophilia C, your hematologist will look for these symptoms, your family history of bleeding (especially if you have known hemophilia C in your lineage), and the results of a clinical evaluation.

A coagulation study to diagnose hemophilia C might include the following:

• CBC
• Activated partial thromboplastin time (aPTT)
• Prothrombin time (PT)
• Bleeding time
• Serum FXI activity
• Thrombin generation tests (still in development)

If you have hemophilia C, your aPTT test will likely be prolonged (taking longer to clot than normal), but your PT tests will likely be normal.

Severity

Even among family members, bleeding symptoms for those with hemophilia C vary a lot. Some people with hemophilia C who have very low FXI levels might have mild symptoms and few bleeds, while some people with hemophilia C who have only slightly low FXI levels might have a great deal of bleeding. This is partly why hemophilia C can be difficult to diagnose.

Inhibitors are autoantibodies (specialized proteins produced by the body’s immune system that target healthy tissue). If you have hemophilia C, you can develop an inhibitor, which can impact the effectiveness of your treatment. The inhibitor is usually found when breakthrough bleeding (bleeding once treatment has begun) or a worsening response to FXI rather than spontaneous bleeding.

If you develop an inhibitor, your hematologist will likely recommend additional therapy, such as FVII. FVII has been used to treat bleeding episodes after surgery, but its use is still in the investigative stages. Current findings are that lower doses combined with antifibrinolytics are effective, but higher doses may cause excessive clotting.